Open AccessSalvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Author(s) -
Christian Gisselbrecht,
Bertram Glaß,
Nicolas Mounier,
Devinder Gill,
David C. Linch,
Marek Trněný,
André Bosly,
Nicolas Ketterer,
Ofer Shpilberg,
Hans Hagberg,
Dávid Ma,
Josette Brière,
Craig H. Moskowitz,
Norbert Schmitz
Publication year - 2010
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2010.28.1618
Subject(s) - medicine , rituximab , dhap , autologous stem cell transplantation , etoposide , salvage therapy , carboplatin , ifosfamide , transplantation , surgery , cytarabine , oncology , international prognostic index , chemotherapy , gastroenterology , lymphoma , cisplatin , enzyme , biochemistry , chemistry
Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Salvage regimens have never been compared; their efficacy in the rituximab era is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom